Leech Phospholipase A2 Inhibitor
Putative PLA2 inhibitor identified in leech salivary transcriptome — candidate eicosanoid-cascade modulator.
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Putative PLA2 inhibitor identified in leech salivary transcriptome — candidate eicosanoid-cascade modulator.
- Evidence level
- Mechanistic discussion
- Drug vs leech
- Purified natural compound
Clinical translation limit
This PLA2 inhibitor is hypothesized only. Sequence-level cataloging does NOT establish anti-inflammatory clinical efficacy. No FDA-approved derivative exists.
Molecular Profile
- Category
- Anti-inflammatory
- Evidence tier
- Preclinical
- Molecular weight
- 15,000 Da
- Source species
- Hirudo medicinalis
- Discovered
- 2018
Biological Targets
- → secretory phospholipase A2 (predicted)
External Resources
Related Anti-inflammatory Compounds
Leech C1 Inhibitor (LCi)
Complement system modulator targeting C1q activation — immunological homeostasis.
Leech Eicosanoid Modulator
Modulates prostaglandin and leukotriene cascades — anti-inflammatory pathway.
Haemadipsa yanyuanensis Progranulin (Hy-PGRN)
Putative progranulin gene with 122 cysteine residues and nine tandem repeats — distinctive structural organization (Lin 2025 chromosome-level genome).
WP-EAGSAKELEGDPVAG
Whitmania pigra-derived 15-residue anti-atherosclerosis peptide — Hu 2020 demonstrates inhibition of macrophage migration via JNK + p38 MAPK pathways.